Business Context and Reporting Period
This Form 8-K filing by Dare Bioscience, Inc. (DARE) is dated January 31, 2020. The report addresses the company's compliance status with Nasdaq Listing Rule 5550(b) regarding minimum stockholders' equity requirements following a notification of non-compliance received in November 2019.
Key Financial Metrics and Capital Structure
- Stockholders' Equity: The company believes it has regained compliance by achieving stockholders' equity of at least $2.5 million.
- Acquisition Proceeds: In November 2019, the acquisition of Microchips Biotech, Inc. contributed $6.1 million in cash and cash equivalents.
- Capital Raised (January 2020): The company raised approximately $6.8 million in net proceeds.
- Capital Breakdown: $5.1 million from the sale of approximately 3.1 million shares via an at-the-market (ATM) facility and $1.7 million from the exercise of approximately 1.7 million warrants.
- Shares Outstanding: As of January 31, 2020, total common stock outstanding was 24,513,675 shares.
- Revenue and Profit: The filing text does not provide specific revenue, profit, or operating margin figures for the period.
Material Changes Versus Prior Period
The primary material change is the restoration of stockholders' equity to meet the $2.5 million Nasdaq threshold. This was achieved through two distinct events: the November 2019 acquisition of Microchips Biotech, which added approximately $2.4 million to paid-in capital, and the January 2020 capital raise of $6.8 million. These actions reversed the non-compliance status reported as of September 30, 2019.
Outlook, Risks, and Management Commentary
Management states that Dare Bioscience believes it has regained compliance with Nasdaq listing standards. However, the filing includes significant risk disclosures:
- Ongoing Monitoring: Nasdaq will continue to monitor the company's compliance.
- Delisting Risk: If the next periodic report does not evidence continued compliance with Rule 5550(b), the company may again be subject to delisting.
- Uncertainty: Management explicitly states there can be no assurance that the company will be able to maintain ongoing compliance with all applicable Nasdaq listing criteria.
Investor Verification Checklist
- Verify the exact stockholders' equity figure in the next quarterly report (10-Q) to confirm sustained compliance with the $2.5 million threshold.
- Monitor for any further correspondence from the Nasdaq Listing Qualifications Staff regarding the company's status.
- Review the integration progress and financial impact of the Microchips Biotech acquisition in subsequent filings.
- Assess the company's cash burn rate and runway given the recent capital raises and lack of reported revenue in this filing.